Compare RCG & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCG | LSTA |
|---|---|---|
| Founded | 1994 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 20.9M |
| IPO Year | N/A | N/A |
| Metric | RCG | LSTA |
|---|---|---|
| Price | $2.57 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 5.9K | ★ 32.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.52 | $1.81 |
| 52 Week High | $1.90 | $4.20 |
| Indicator | RCG | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 43.33 |
| Support Level | $2.50 | $1.85 |
| Resistance Level | $2.60 | $2.17 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 48.00 | 47.76 |
RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.